Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid-range and preserved ejection fraction.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
10 2019
Historique:
received: 30 01 2019
revised: 03 05 2019
accepted: 26 06 2019
pubmed: 22 7 2019
medline: 9 6 2020
entrez: 21 7 2019
Statut: ppublish

Résumé

Heart failure (HF) is classified into three types according to left ventricular ejection fraction (EF). The effect of blood pressure (BP) on the pathogenesis of each type is assumed to be different. However, the association between the prognosis of each type of HF and abnormal BP variations assessed by ambulatory BP monitoring (ABPM), such as nocturnal hypertension and the riser pattern, remains unclear. We studied 325 consecutive patients with decompensated HF who were acutely admitted to our hospital and underwent ABPM at discharge. During a mean follow-up of 30.0 months, 52 cardiovascular and 112 all-cause deaths occurred. The Cox proportional hazards model showed that the mean values of 24 h, awake, and sleep-time systolic BP (SBP), and abnormal 24 h ABPM patterns, such as nocturnal hypertension and non-dipper pattern, were not associated with either all-cause or cardiovascular mortality in patients with HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF), or HF with preserved EF (HFpEF), except for sleep-time SBP in HFrEF. However, the riser pattern was a significant and independent predictor of all-cause and cardiovascular deaths in patients with HFpEF (hazard ratio, 2.01; 95% confidence interval, 1.12-3.62; 0.0200; and hazard ratio, 2.48; 95% confidence interval, 1.08-5.90; 0.0332, respectively). Sleep-time pulse rate was similarly decreased in both the riser and non-riser groups. The riser pattern of SBP was associated with an increased risk of adverse outcomes among patients with HFpEF but not HFrEF or HFmrEF.

Identifiants

pubmed: 31325235
doi: 10.1002/ehf2.12500
pmc: PMC6816074
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1057-1067

Subventions

Organisme : Japan Agency for Medical Research and Development
Pays : International
Organisme : Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labor, and Welfare of Japan
Pays : International

Informations de copyright

© 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

J Am Coll Cardiol. 2015 Nov 10;66(19):2059-2071
pubmed: 26541915
Clin Hypertens. 2016 Jul 12;22:16
pubmed: 27413538
Card Fail Rev. 2018 May;4(1):50-53
pubmed: 29892478
Eur Heart J. 2013 Sep;34(36):2823-9
pubmed: 23864130
Circ J. 2015;79(10):2209-15
pubmed: 26227392
J Hypertens. 2002 Nov;20(11):2183-9
pubmed: 12409956
Am J Kidney Dis. 1999 Jan;33(1):29-35
pubmed: 9915264
Circ J. 2013;77(11):2766-71
pubmed: 23978791
Eur J Heart Fail. 2009 Sep;11(9):855-62
pubmed: 19654140
Am J Physiol Heart Circ Physiol. 2016 Apr 1;310(7):H813-20
pubmed: 26747499
J Cardiol. 2010 Jan;55(1):13-22
pubmed: 20122544
ESC Heart Fail. 2018 Aug;5(4):685-694
pubmed: 29660263
J Am Heart Assoc. 2014 Nov 04;3(6):e001174
pubmed: 25370599
Am J Hypertens. 2014 May;27(5):680-7
pubmed: 24061070
JAMA. 1999 Aug 11;282(6):539-46
pubmed: 10450715
Hypertension. 2001 Oct;38(4):852-7
pubmed: 11641298
Hypertension. 2005 Feb;45(2):240-5
pubmed: 15596571
Hypertension. 2014 Jan;63(1):105-11
pubmed: 24126172
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
Circ J. 2017 Jan 25;81(2):220-226
pubmed: 28025460
J Card Fail. 2014 Mar;20(3):174-80
pubmed: 24361802
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
JAMA. 2006 Nov 8;296(18):2217-26
pubmed: 17090768
Circulation. 2005 Apr 12;111(14):1777-83
pubmed: 15809377
J Hypertens. 2015 Nov;33(11):2257-64
pubmed: 26425836
ESC Heart Fail. 2019 Oct;6(5):1057-1067
pubmed: 31325235
N Engl J Med. 2006 Jul 20;355(3):260-9
pubmed: 16855266
Am J Hypertens. 2003 Jun;16(6):434-8
pubmed: 12799090
JAMA Cardiol. 2018 Apr 1;3(4):288-297
pubmed: 29450487
ESC Heart Fail. 2017 Aug;4(3):198-202
pubmed: 28772039
ESC Heart Fail. 2018 Jun;5(3):284-291
pubmed: 29460495
J Card Fail. 2007 Oct;13(8):656-62
pubmed: 17923358
J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A
pubmed: 8376698
Circ J. 2015;79(6):1307-14
pubmed: 25753468
Lancet. 2007 Oct 6;370(9594):1219-29
pubmed: 17920917
Card Fail Rev. 2017 Nov;3(2):134-139
pubmed: 29387467

Auteurs

Tomoya Ueda (T)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Rika Kawakami (R)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Yasuki Nakada (Y)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Tomoya Nakano (T)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Hitoshi Nakagawa (H)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Masaru Matsui (M)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Taku Nishida (T)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Kenji Onoue (K)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Tsunenari Soeda (T)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Satoshi Okayama (S)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Makoto Watanabe (M)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Hiroyuki Okura (H)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Yoshihiko Saito (Y)

Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634-8522, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH